Minimally invasive surgical approaches are not only here to stay in spinal care, they are likely to continue growing as a percentage of overall cases. That's great news for NuVasive (NASDAQ:NUVA), as is progress toward the sort of operating margins that would normally be expected of a quality med-tech company. While a failure to get clean operating margins above 20% looms as a long-term risk for this company, as does competition, the ongoing consolidation in the orthopedics space may well make that somebody else's problem. I'm always a little leery of jumping into a story that is already up 50% over the past year, but I can't rule out the potential upside as investors covet growth stories in...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|